Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report

Simple item page
dc.contributor.authorRamos, German. E. E.
dc.contributor.authorCaglevic, Christian
dc.contributor.authorBulnes, Juan. F. F.
dc.contributor.authorPanay, Sergio. E. E.
dc.contributor.authorZapata, Mario. I. I.
dc.contributor.authorDaniele, Andres J.
dc.contributor.authorRodriguez, Manuel. E. E.
dc.date.accessioned2025-01-20T21:01:16Z
dc.date.available2025-01-20T21:01:16Z
dc.date.issued2022
dc.description.abstractEndothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.
dc.fuente.origenWOS
dc.identifier.doi10.3389/fcvm.2022.1060813
dc.identifier.issn2297-055X
dc.identifier.urihttps://doi.org/10.3389/fcvm.2022.1060813
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92848
dc.identifier.wosidWOS:000893774000001
dc.language.isoen
dc.revistaFrontiers in cardiovascular medicine
dc.rightsacceso restringido
dc.subjectTakotsubo (stress) cardiomyopathy
dc.subjectAfatinib
dc.subjectEGFR mutation
dc.subjecttyrosine kinase inhibition
dc.subjectNSCLC
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleTakotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
dc.typeartículo
dc.volumen9
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas